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Abstract 
Evans Syndrome is a rare autoimmune dis-
ease consisting of hemolytic anemia, thrombo-
cytopenia and/or neutropenia. It may be asso-
ciated with other autoimmune or lymphoprolif-
erative diseases. Its course can be extremely
serious and, rarely, even life-threatening; thus
it represents a excellent treatment challenge
for the pediatric hematologist. First line treat-
ment consists of steroids and/or immunoglob-
ulin;  further  therapy  with  rituximab,  vin-
cristine, cyclophosphamide and other immu  -
nosuppressive  drugs  can  be  considered  in
unresponsive  patients.  We  describe  a  baby
with refractory Evans Syndrome that was cured
by prolonged administration of mycophenolate
mofetil and remained disease-free for 4 years
after the discontinuation of treatment.
Introduction
Evans  Syndrome  (ES)  is  an  autoimmune
disorder  characterized  by  thrombocytopenia
and/or neutropenia associated with hemolytic
anemia (AHA).1-3 It is a potentially life-threat-
ening condition that may be associated with
other underlying autoimmune or lymph-prolif-
erative  disorders.4 Standard  treatment  con-
sists  of  transfusions,  corticosteroids  and
immunoglobulins  (IVIG);  second-line  treat-
ment in ES evolved over the last decade, and
includes at present anti-CD20 rituximab, vin-
cristine,  alkalizing  agents,  mycophenolate
mofetil  (MMF)  or  cyclosporine  (CyA).5-6,8-14
Long-term remissions induced by splenectomy
are  less  frequent  than  in  uncomplicated
immune  thrombocytopenia  purpura  (ITP).
This menu challenges the hematologist to pick
the  best  option  suitable  for  each  specific
patient even though, above all in younger chil-
dren, the course of ES can be extremely seri-
ous.4 Sometimes it can be difficult to choose
the best treatment.
Case Report
A.G., female, 18 months, was initially diag-
nosed with ITP, only transiently responsive to
IVIG (1 g/kg) and refractory to oral prednisone
(2 mg/kg/day for two weeks). After one month,
soon  after  prednisone  stop,  she  developed
palor, petecchiae, skin and conjunctive jaun-
dice and mild hepatomegaly (liver margin pal-
pable at 3 cm below the costal margin). 
Blood  count  showed:  Hb  5.3  g/dL,  RBC
1,730,000/ʼL,  MCV  93.6  fl,  WBC  12,970/ʼL,
PLTS  4,000/ʼL,  reticulocytes  22.5%;  direct
antiglobulin test (DAT) and indirect antiglobu-
lin test extremely positive (with IgG specifici-
ty), LDH 525 u/L, AST 48 u/L, ALT 14 u/L, biliru-
bin direct/total 0.68/4.1 mg/dL. On the basis of
the finding of AHA, the diagnosis was changed
from ITP into ES. Screening for autoantibodies
(ANA, ENA, anti-DNA, AMA, ASMA) was com-
pletely negative. 
The baby was refractory to several lines of
treatment:  IVIG  (1  g/kg),  oral  prednisone 
(2  mg/kg/day  for  two  weeks),  intravenous
methylprednisolone  (25  mg/kg/day  for  three
consecutive days), rituximab i.v. (four weekly
doses  at  375  mg/sqm),  vincristine  i.v.  (1.5
mg/sqm), cyclophosphamide i.v. (600 mg/sqm),
thus remaining completely dependent on both
erythrocyte and platelet transfusions for about
four  months.  Finally  oral  CyA  (5  mg/kg/day)
was started; this therapy made the baby imme-
diately  transfusion-free  with  Hb  ranging
between 7 and 12 g/dL, positive DAT and retic-
ulocytes count of more than 15%. Interestingly,
thrombocytopenia  persisted  (<5,000/ʼL)  and
became  symptomatic  with  frequent  bleeding
into the skin and mucous membranes. 
After  six  months,  therapy  with  MMF  was
started  (50  mg/kg/die)  and  CyA  was  slowly
tapered over 2 months. A stable increase of
hemoglobin  (>12  g/dL)  and  platelets
(>20,000/ʼl)  was  observed  after  2  months
(soon after the discontinuation of CyA), and 4
months of MMF therapy, respectively. On day
45 of MMF therapy, the DAT became almost
negative  and  reticulocyte  count  dropped  to
<2%. A normal platelet count (>150.000/ʼL)
was documented since 8 months of MMF ther-
apy. No adverse drug-related effect was noted.
After 1 year, MMF was slowly tapered and then
stopped  in  nine  months  (about  22  months
after  the  beginning  of  treatment).  DAT
remained negative since 12 months after dis-
continuation of MMF. Figures 1 and 2 show
hemoglobin  and  platelets  levels  respectively
during the whole period of observation. Now
the girl is well, in complete remission 6 years
after diagnosis and about 48 months after com-
pletion of therapy.  
Discussion
Treatment of ES is often troublesome, espe-
cially in cases with reticulocytopenia, resulting
from IgM autoagglutinins, or in infants, when
the course can be extremely serious or fatal.4
Despite novel treatment modalities, standard
therapy remains to be established. Steroid and
IVIG are the traditional first-line therapies,1,4,5
but a B-cell targeted therapy with the use of a
mouse/human chimeric IgG1 anti-CD20 mono-
clonal antibody, rituximab, has gained wide-
spread acceptance in cases refractory to more
conventional treatment; suppression of auto-
reactive B cells may explain the response.6 
However, many issues still remain, including
optimal dose, long-term effectiveness and side
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effects. Recently the association of Progressive
Multifocal Leukoencephalopathy (PML) with rit-
uximab (although the absolute risk of develop-
ing PML is low), has raised some doubts about
the  use  of  anti-CD20  in  non-oncological  dis-
eases.7  Our patient with ES was refractory to
steroids, IVIG and rituximab. Due to the age and
the limited chance of cure, we did not advise
splenectomy. Chemotherapeutic agents like vin-
cristine or cyclophosphamide, sporadically used
with equivocal results, also proved ineffective in
our patient.8,9
Sporadic reports suggested a potential effect
of  MMF  and  CyA,  two  immunosuppressive
drugs.10-14 We decided to start with CyA, rela-
tively  more  often  reported,  at  a  dose  of  5
mg/kg/day. The effect on red blood cell transfu-
sion  dependency  was  immediate:  after  the
start of CyA the child was transfused only one
time.  Unfortunately  there  was  no  effect  on
platelet count, and the child’s quality of life
was hampered by persistent skin and mucosal
bleeding. Thus, we decided to add MMF to CyA.
The combined therapy rapidly demonstrated a
stronger  activity  than  previous  monotherapy
with CyA. Hemoglobin increased to >12 g/dL
and  reticulocytes  dropped  to  <2%.
Cyclosporine was stopped after two months of
combined use with MMF and no sign of AHA
relapse was noted. The clinical signs of throm-
bocytopenia  started  to  decrease  about  three
months after beginning the drug, but a normal
count  of  platelets  was  achieved  only  after  8
months of MMF therapy, so we are not able to
confirm that the resolution is surely due to the
effect of the drug. 
Cyclosporine  suppresses  the  immune
response  by  inhibiting  the  action  of  cal-
cineurin, which results in a failure to activate
the genes required for B-cell help and for T-cell
proliferation, whereas MMF, reducing guanine
nucleotide pools in lymphocytes, inhibits pro-
liferative responses of T- and B-lymphocytes to
both  mitogenic  and  allospecific  stimulation.
Due to lack of such reports, we cannot assess
if  in  our  case  some  synergy  between  the
immune-suppressors may have occurred.
In conclusion, we suggest that based on our
experience  in  this  case,  the  combination  of
MMF and CyA could be considered after more
conventional drugs (IVIG, steroid, rituximab)
or  other  second  choice  drugs  (vincristine,
cyclophosphamide)  have  failed.  For  patients
failing  after  several  lines  of  treatment,  and
remaining in life-threatening condition, allo-
geneic hematopoietic stem cell transplantation
(HSCT) should be considered, especially if an
HLA-identical donor is available in the family.15
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Figure 1. Haemoglobin trend during the observation period.
Figure 2. Platelets count during the observation period.